Adherence and Persistence After Switching Warfarin to Direct Oral Anticoagulants
This systematic review is the first structured synthesis of post-switch medication-taking behavior after patients move from a vitamin K antagonist (VKA) to a direct oral anticoagulant (DOAC), and it shows that reassuring headline numbers rest on weak, non-comparable evidence.
📅 Journal publication: Aug 1, 2026·Last updated: Nov 5, 2026
vitamin K antagonistwarfarindirect oral anticoagulantsDOACapixabanrivaroxabandabigatranadherencepersistenceproportion of days coveredatrial fibrillationvenous thromboembolismanticoagulation switchingsystematic reviewanticoagulation stewardshipAnticoagulation / Hematology
Background Information
Switching to DOACs? Adherence high, but persistence varies.
Switching from vitamin K antagonists (VKAs) to direct oral anticoagulants (DOACs) poses adherence and persistence challenges that impact treatment efficacy. Objective adherence rates after switching were generally high (76% to 97.5% achieving PDC ≥ 80%), though persistence varied widely (54% to 94%). Although adherence rates were high, variability in persistence suggests a need for standardized evaluation and adherence support after switching anticoagulants. Adherence is generally high when switching from VKAs to DOACs, but persistence varies, necessitating standardized evaluations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Alaqab A, Alfaqeeh M, Hashim R, Mustafa M, Hamad A, Abu-Rmeileh NME, Abdulah R, Alfian SD
Citation:Alaqab A, Alfaqeeh M, Hashim R, et al. Medication adherence and treatment persistence following switching from vitamin K antagonists to direct oral anticoagulants: a systematic review. BMC cardiovascular disorders. 2026;26(1). doi:10.1186/s12872-026-06398-0